Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2024-08-08 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2024
Earnings Release Classification · 1% confidence The document is titled "Genmab Updates 2024 Financial Guidance" and provides revised financial outlooks (revenue, operating profit) for the year 2024, comparing them to previous guidance. It explicitly mentions that the full financial results for the first six months of 2024 will be published immediately following this announcement. This structure—an announcement updating forward-looking financial metrics rather than presenting the full periodic results—is characteristic of an Earnings Release (ER), which provides key highlights before the comprehensive report (like an IR or 10-K). Although it references the 'Interim Report for the first quarter of 2024', the document itself is a focused update on guidance, making ER the most appropriate classification over IR (Interim Report) or MDA (Management Discussion & Analysis). The document length is substantial (nearly 10,000 characters), ruling out a simple RPA/RNS based on the 'MENU VS MEAL' rule, as it contains significant narrative and data tables, not just a pointer to an attachment. H1 2024
2024-08-08 English
Genmab Updates 2024 Financial Guidance
Earnings Release Classification · 1% confidence The document is a 'Company Announcement' from Genmab regarding an update to its 2024 financial guidance. It provides revised revenue and operating profit projections following an acquisition. While it discusses financial figures, it is an initial announcement of guidance updates rather than the full interim or annual report itself. According to the 'Menu vs Meal' rule, this is a regulatory announcement regarding financial expectations, which fits best under the 'Earnings Release' (ER) category as it details key financial highlights and guidance updates prior to the full report release. FY 2024
2024-08-08 English
6-K
Foreign Filer Report
2024-08-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 1% confidence The document is titled "Company Announcement" and details a strategic decision regarding a drug development program (Acasunlimab), specifically BioNTech opting out and Genmab taking full control. It includes key business updates, clinical trial status, and financial guidance impact. This type of material, which announces a significant corporate event or strategic shift outside of routine financial reporting (like 10-K or ER), is typically disseminated via a broad regulatory filing or press release. Since it is a formal announcement of a material event and does not fit the specific definitions for M&A (TAR), Capital Change (CAP/SHA), or Director Dealing (DIRS), it falls best under the general category for regulatory announcements or press releases. Given the context of a major corporate action announcement, it is most appropriately classified as a Regulatory Filing (RNS), which serves as the general category for miscellaneous regulatory announcements not covered by more specific codes. The length (7345 chars) confirms it is a substantive announcement, not just a brief notice of publication (RPA).
2024-08-05 English
Genmab Takes Full Control of Acasunlimab Development Program
Regulatory Filings Classification · 1% confidence The document is a 'Company Announcement' from Genmab regarding a change in their development program for acasunlimab. It is under 5,000 characters of core content (excluding boilerplate/metadata), explicitly labeled as a 'Company Announcement', and includes an 'Attachment' link at the bottom, which triggers the 'Report Publication Announcement' (RPA) classification under the 'Menu vs Meal' rule.
2024-08-05 English
6-K
Foreign Filer Report
2024-07-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.